(2-azaniumyl-3-hydroxyoctadecyl) hydrogen phosphate

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 鞘脂
• 英文名称: (2-azaniumyl-3-hydroxyoctadecyl) hydrogen phosphate
• 化学式: C18H40NO5P
• 分子量: 381.5
• InChiKey: YHEDRJPUIRMZMP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  25
• 可旋转键数：
  18
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  113
• 氢给体数：
  4
• 氢受体数：
  6

文献信息

• LPA receptor agonists and antagonists and methods of use
  申请人：——

  公开号：US20030130237A1

  公开（公告）日：2003-07-10

  The present invention relates to compounds according to formula (I) as disclosed herein as well as pharmaceutical compositions which include those compounds. Also disclosed are methods of using such compounds, which have activity as agonists or as antagonists of LPA receptors; such methods including inhibiting LPA activity on an LPA receptor, modulating LPA receptor activity, treating cancer, enhancing cell proliferation, treating a wound, treating apoptosis or preserving or restoring function in a cell, tissue, or organ, culturing cells, preserving organ or tissue function, and treating a dermatological condition.

  本发明涉及根据所述的化合物的化学式(I)，以及包括这些化合物的药物组合物。还公开了使用这些化合物的方法，这些方法具有作为LPA受体的激动剂或拮抗剂的活性；这些方法包括抑制LPA对LPA受体的活性，调节LPA受体的活性，治疗癌症，增强细胞增殖，治疗伤口，治疗凋亡或保护或恢复细胞、组织或器官的功能，培养细胞，保护器官或组织功能，以及治疗皮肤病症。
• [EN] ENZYME INTERACTING AGENTS<br/>[FR] AGENTS D'INTERACTION AVEC DES ENZYMES
  申请人：UNIV MONASH

  公开号：WO2015196258A1

  公开（公告）日：2015-12-30

  The present disclosure relates generally, but not exclusively, to compounds and their use as enzyme interacting agents, in particular, agents which interact with one or more enzymes in the sphingolipid biosynthesis pathway. The disclosure further relates to the use of such 5 compounds as research tools, use in therapy, to compositions and agents comprising said compounds, and to methods of treatment using said compounds.

  本公开涉及一般性地，但不仅限于化合物及其用作酶相互作用剂的用途，特别是与鞘脂类生物合成途径中的一个或多个酶相互作用的剂。本公开进一步涉及将这些化合物用作研究工具、治疗用途、包含所述化合物的组合物和剂，以及使用这些化合物进行治疗的方法。
• LPA Receptor Agonists and Antagonists and Methods of Use
  申请人：Miller D. Duane

  公开号：US20080090783A1

  公开（公告）日：2008-04-17

  Disclosed are compounds according to formula (I) as well as pharmaceutical compositions which include those compounds. Also disclosed are methods of using such compounds, which have activity as agonists or as antagonists of LPA receptors; such methods including inhibiting LPA activity on an LPA receptor, modulating LPA receptor activity, treating cancer, enhancing cell proliferation, treating a wound, treating apoptosis or preserving or restoring function in a cell, tissue, or organ, culturing cells, preserving organ or tissue function, and treating a dermatological condition.

  本发明涉及化合物(I)及包含该化合物的药物组合物。还揭示了使用这些化合物的方法，这些方法具有作为LPA受体激动剂或拮抗剂的活性；这些方法包括抑制LPA受体上的LPA活性，调节LPA受体活性，治疗癌症，增强细胞增殖，治疗创伤，治疗凋亡或保护或恢复细胞、组织或器官的功能，培养细胞，保护器官或组织功能，以及治疗皮肤病症。
• LPA RECEPTOR AGONISTS AND ANTAGONISTS AND METHODS OF USE
  申请人：Miller Duane D.

  公开号：US20120135967A1

  公开（公告）日：2012-05-31

  Disclosed are compounds according to formula (I) as well as pharmaceutical compositions which include those compounds. Also disclosed are methods of using such compounds, which have activity as agonists or as antagonists of LPA receptors; such methods including inhibiting LPA activity on an LPA receptor, modulating LPA receptor activity, treating cancer, enhancing cell proliferation, treating a wound, treating apoptosis or preserving or restoring function in a cell, tissue, or organ, culturing cells, preserving organ or tissue function, and treating a dermatological condition.

  本发明公开了按照公式(I)的化合物，以及包括这些化合物的制药组合物。还公开了使用这些化合物的方法，这些化合物具有作为LPA受体的激动剂或拮抗剂的活性。这些方法包括抑制LPA在LPA受体上的活性，调节LPA受体活性，治疗癌症，增强细胞增殖，治疗伤口，治疗凋亡或保护或恢复细胞、组织或器官的功能，培养细胞，保护器官或组织功能以及治疗皮肤病条件。
• Method Of Treating Acute Lung Injury Using Sphingosine 1 Phosphate Analogs Or Sphingosine 1 Phosphate Receptor Agonists
  申请人：Garcia Joe G.N.

  公开号：US20130079309A1

  公开（公告）日：2013-03-28

  The invention provides methods for treating or reducing the risk of developing acute lung injury manifested by increased vascular permeability. Also provided are pharmaceutical compositions comprising an FTY720 analog or derivative and/or SEW 2871 for use in the disclosed methods. The invention also provides methods for treating or reducing the risk of developing acute lung injury resulting from dysregulation of ceramide/sphingolipid pathway, more specifically, acute lung injury resulting from radiation.

  本发明提供了治疗或减少因增加血管通透性而表现为急性肺损伤的方法。还提供了包含FTY720类似物或衍生物和/或SEW 2871的药物组合物，用于所述方法。本发明还提供了治疗或减少因鞘氨醇/鞘脂代谢通路失调而导致的急性肺损伤的方法，更具体地说，是由放射线引起的急性肺损伤。